Browse by category

Fractyl Health has announced positive 6-month results from its open-label REVEAL-1 Cohort. The REVEAL-1 Cohort is an open-label study in individuals with obesity who have lost at least 15% of their total body weight on a GLP-1 medication and who either need or choose to discontinue GLP-1 therapy. The REVEAL-1 data show that patients who underwent a single Revita procedure after discontinuing GLP-1 therapy maintained both stable body weight and glycaemic control through 6 mont

Fractyl Health is prioritising its REMAIN-1 pivotal study, addressing the demand for an off-ramp to GLP-1 drugs, while advancing its...